Finished medicines exported to the UK using EU-imported active ingredients (APIs): can they be cumulated? The answer is no — and this is the core EVFTA–UKVFTA difference pharma businesses most often miss. The UKVFTA (in force 01/05/2021) is a separate agreement: EU-originating materials cannot be cumulated for UK-bound goods.
1. Why pharma is hit hardest by cumulation
Pharma supply chains are deeply globalised: APIs from India, China and the EU; excipients from many sources; packing in Viet Nam. For EU-bound goods under the EVFTA, EU-originating APIs cumulate — making the non-originating value ratio easy to meet. But the same tablet shipped to the UK under the UKVFTA: EU-originating APIs count as non-originating materials within the HS Chapter 30 product rule’s value cap. Result: the same formula earns the preference for the EU and misses it for the UK.
2. Recalculating the origin formula for the UK market
Pharma exporters to the UK need to: (a) keep origin worksheets dedicated to the UK market — never reuse the EU worksheet; (b) recompute the non-originating value ratio with EU APIs “removed” from cumulation — if over the threshold, substitute EU APIs with Vietnamese/UK-originating APIs or APIs originating under the UKVFTA; (c) cite the UKVFTA correctly on origin documents with criterion “W” and the HS code. In practice, many pharma firms discover the problem only when UK customs denies the preference — by then the shipment bears MFN duty and the customer’s trust is gone.
3. The general lesson: one product, two origin maps
The principle applies across industries, but pharma illustrates it most sharply because APIs are expensive and value-heavy — a small cumulation change swings the ratio hard. Exporters serving both the EU and the UK must run two parallel origin-calculation systems, updated whenever an API supplier changes. Cumulation is not back-office technicality — it is a variable that decides the quoted price.
Conclusion
A UK-bound tablet does not “inherit” the EU origin of its API. In the post-Brexit world, each market has its own cumulation map — and pharma is where that map costs the most.
Frequently Asked Questions
Can EU-originating APIs be cumulated for UK-bound medicines?
No. The UKVFTA operates independently of the EVFTA; EU-originating APIs count as non-originating materials within the HS Chapter 30 product rule’s value cap.
Why is pharma hit hardest by cumulation?
APIs are expensive and value-heavy — a small cumulation change swings the non-originating value ratio hard; the same formula can earn the EU preference yet miss the UK one.
What must pharma exporters to the UK do?
Keep UK-dedicated origin worksheets; recompute the ratio with EU APIs removed from cumulation; substitute EU APIs with Vietnamese/UK-originating APIs if over threshold; cite the UKVFTA correctly.
When do businesses usually discover cumulation problems?
Too late — when UK customs denies the preference and the shipment already bears MFN duty. Calculate before contracting with UK buyers, not after denial.
